Spruce Street Capital LP Takes Position in Maze Therapeutics, Inc. $MAZE

Spruce Street Capital LP purchased a new stake in Maze Therapeutics, Inc. (NASDAQ:MAZE) in the first quarter, Holdings Channel.com reports. The firm purchased 200,000 shares of the company’s stock, valued at approximately $5,970,000. Maze Therapeutics makes up about 1.4% of Spruce Street Capital LP’s investment portfolio, making the stock its 22nd biggest position.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Royal Bank of Canada grew its holdings in Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after acquiring an additional 363 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Maze Therapeutics in the fourth quarter worth about $39,000. Ameritas Investment Partners Inc. raised its stake in shares of Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after acquiring an additional 738 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Maze Therapeutics during the fourth quarter worth approximately $43,000. Finally, Russell Investments Group Ltd. lifted its position in shares of Maze Therapeutics by 947.8% during the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after purchasing an additional 1,725 shares in the last quarter.

Analyst Ratings Changes

A number of brokerages recently weighed in on MAZE. Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Truist Financial reduced their price objective on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a report on Tuesday, April 14th. Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, JPMorgan Chase & Co. lifted their target price on Maze Therapeutics from $52.00 to $58.00 and gave the company an “overweight” rating in a research note on Tuesday, March 31st. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Maze Therapeutics presently has a consensus rating of “Buy” and an average price target of $66.00.

Maze Therapeutics Stock Performance

Maze Therapeutics stock opened at $27.68 on Friday. The company has a current ratio of 17.88, a quick ratio of 17.88 and a debt-to-equity ratio of 0.11. Maze Therapeutics, Inc. has a 1 year low of $12.81 and a 1 year high of $53.65. The company has a market cap of $1.53 billion, a PE ratio of -10.94 and a beta of 2.14. The company’s 50-day moving average is $27.10 and its two-hundred day moving average is $34.46.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The firm had revenue of $20.00 million for the quarter. Equities analysts anticipate that Maze Therapeutics, Inc. will post -2.73 earnings per share for the current year.

Insider Activity at Maze Therapeutics

In other Maze Therapeutics news, insider Atul Dandekar sold 7,500 shares of the firm’s stock in a transaction that occurred on Wednesday, April 29th. The shares were sold at an average price of $25.37, for a total value of $190,275.00. Following the transaction, the insider directly owned 10,503 shares of the company’s stock, valued at approximately $266,461.11. This trade represents a 41.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of Maze Therapeutics stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $29.98, for a total transaction of $1,034,339.98. Following the sale, the chief executive officer directly owned 23,337 shares of the company’s stock, valued at $699,643.26. This represents a 59.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 141,470 shares of company stock worth $3,887,939 over the last ninety days. Company insiders own 5.30% of the company’s stock.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.